Mesoporous silica- and silicon-based materials ... - Helda - Helsinki.fi

More documents

Recommendations

Info

Iler, R.K., 1979. Chemistry of silica - solubility, polymerization, colloid and surface properties and biochemistry. John Wiley & Sons, New York, USA. Izquierdo-Barba, I., Martinez, Á., Doadrio, A.L., Pérez-Pariente, J., Vallet-Regí, M., 2005. Release evaluation of drugs from ordered three-dimensional silica structures. Eur. J. Pharm. Sci. 26, 365-373. Jakubowicz, J., Smardz, K., Smardz, L., 2007. Characterization of porous silicon prepared by powder technology. Physica E Low Dimens. Syst. Nanostruct. 38, 139-143. Jannin, V., Musakhanian, J., Marchaud, D., 2008. Approaches for the development of solid and semi-solid lipid-based formulations. Adv. Drug Delivery Rev. 60, 734-746. Janssens, S., Van den Mooter, G., 2009. Review: Physical chemistry of solid dispersions. J. Pharm. Pharmacol. 61, 1571-1586. Jugdaohsingh, R., Anderson, S.H., Tucker, K.L., Elliott, H., Kiel, D.P., Thompson, R.P., Powell, J.J., 2002. Dietary silicon intake and absorption. Am. J. Clin. Nutr. 75, 887 -893. Jugdaohsingh, R., Tucker, K.L., Qiao, N., Cupples, L.A., Kiel, D.P., Powell, J.J., 2003. Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort. J. Bone Miner. Res. 19, 297-307. Kansy, M., Senner, F., Gubernator, K., 1998. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41, 1007-1010. Karanth, H., Shenoy, V.S., Murthy, R.R., 2006. Industrially feasible alternative approaches in the manufacture of solid dispersions: A technical report. AAPS PharmSciTech 7, E31-E38. Kawakami, K., 2009. Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases. J. Pharm. Sci. 98, 2875-2885. Kenawy, E.-R., Bowlin, G.L., Mansfield, K., Layman, J., Simpson, D.G., Sanders, E.H., Wnek, G.E., 2002. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J. Controlled Release 81, 57-64. Kerns, E.H., Di, L., 2003. Pharmaceutical profiling in drug discovery. Drug Discov. Today 8, 316- 323. Kilpeläinen, M., Mönkäre, J., Vlasova, M.A., Riikonen, J., Lehto, V.-P., Salonen, J., Järvinen, K., Herzig, K.-H., 2011. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. Eur. J. Pharm. Biopharm. 77, 20-25. Kilpeläinen, M., Riikonen, J., Vlasova, M.A., Huotari, A., Lehto, V.P., Salonen, J., Herzig, K.H., Järvinen, K., 2009. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. J. Controlled Release 137, 166-170. Kim, H.-J., Matsuda, H., Zhou, H., Honma, I., 2006. Ultrasound-triggered smart drug release from a poly(dimethylsiloxane)–mesoporous silica composite. Adv. Mater. 18, 3083-3088. Kim, J., Kim, H.S., Lee, N., Kim, T., Kim, H., Yu, T., Song, I.C., Moon, W.K., Hyeon, T., 2008. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a 52
mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew. Chem. 120, 8566-8569. Kinnari, P., Mäkilä, E., Heikkilä, T., Salonen, J., Hirvonen, J., Santos, H.A., 2011. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int. J. Pharm. n/a, n/a. doi:10.1016/j.ijpharm.2011.05.021. Kortesuo, P., Ahola, M., Karlsson, S., Kangasniemi, I., Yli-Urpo, A., Kiesvaara, J., 2000. Silica xerogel as an implantable carrier for controlled drug delivery - evaluation of drug distribution and tissue effects after implantation. Biomaterials 21, 193-198. Kosuge, K., Sato, T., Kikukawa, N., Takemori, M., 2004. Morphological control of rod- and fiberlike SBA-15 type mesoporous silica using water-soluble sodium silicate. Chem. Mater. 16, 899-905. Kozlova, S.A., Kirik, S.D., 2010. Post-synthetic activation of silanol covering in the mesostructured silicate materials MSM-41 and SBA-15. Microporous Mesoporous Mater. 133, 124-133. Kresge, C.T., Leonowicz, M.E., Roth, W.J., Vartuli, J.C., Beck, J.S., 1992. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359, 710-712. Lai, C.-Y., Trewyn, B.G., Jeftinija, D.M., Jeftinija, K., Xu, S., Jeftinija, S., Lin, V.S.-Y., 2003. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J. Am. Chem. Soc. 125, 4451-4459. Lakshman, J.P., Cao, Y., Kowalski, J., Serajuddin, A.T.M., 2008. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. Mol. Pharmaceutics 5, 994-1002. Laza-Knoerr, A.L., Gref, R., Couvreur, P., 2010. Cyclodextrins for drug delivery. J. Drug Targeting 18, 645-656. Lee, C.-H., Cheng, S.-H., Wang, Y.-J., Chen, Y.-C., Chen, N.-T., Souris, J., Chen, C.-T., Mou, C.- Y., Yang, C.-S., Lo, L.-W., 2009. Near-infrared mesoporous silica nanoparticles for optical imaging: Characterization and in vivo biodistribution. Adv. Funct. Mater. 19, 215-222. Lee, C.-H., Lo, L.-W., Mou, C.-Y., Yang, C.-S., 2008. Synthesis and characterization of positivecharge functionalized mesoporous silica nanoparticles for oral drug delivery of an antiinflammatory drug. Adv. Funct. Mater. 18, 3283-3292. Lehmann, V., Grüning, U., 1997. The limits of macropore array fabrication. Thin Solid Films 297, 13-17. Lehmann, V., Stengl, R., Luigart, A., 2000. On the morphology and the electrochemical formation mechanism of mesoporous silicon. Mater. Sci. Eng., B 69-70, 11-22. Lennernäs, H., Abrahamsson, B., 2005. The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension. J. Pharm. Pharmacol. 57, 273- 285. 53
Page 1 and 2:
Division of Pharmaceutical Technolo
Page 3 and 4:
Abstract New chemical entities with
Page 5 and 6:
Contents Abstract i Acknowledgement
Page 7 and 8:
List of original publications This
Page 9:
PAMPA parallel artificial membrane
Page 12 and 13: lipophilic drugs. The drug molecule
Page 14 and 15: 2 Review of the literature 2.1 Proc
Page 16 and 17: the crystalline API into amorphous
Page 18 and 19: Other solvent methods Spray-freeze-
Page 20 and 21: particles grow and finally start to
Page 22 and 23: 2.2.2.2 Surface chemistry Surface i
Page 24 and 25: Cancer (IARC) has classified inhale
Page 26 and 27: investigation. The cytotoxicity of
Page 28 and 29: The shape and surface properties of
Page 30 and 31: egard to the material toxicity. The
Page 32 and 33: entrapment of the molecules inside
Page 34 and 35: thus leaving the pores open for the
Page 36 and 37: ongoing and it is anticipated that
Page 38 and 39: 4 Experimental Detailed description
Page 40 and 41: 4.1.3 Cell culture (IV) Human colon
Page 42 and 43: espective original publications (I-
Page 44 and 45: Monolayer integrity was controlled
Page 46 and 47: groups/nm 2 , OH, is generally high
Page 48 and 49: However, the HPLC drug loading degr
Page 50 and 51: Figure 7. Release profiles of ibupr
Page 52 and 53: evaluated at pH 1.2 in publication
Page 54 and 55: 6 Conclusions In this study several
Page 56 and 57: Bahl, D., Bogner, R.H., 2006. Amorp
Page 58 and 59: Chang, J.-S., Chang, K.L.B., Hwang,
Page 60 and 61: Gomez-Orellana, I., 2005. Strategie
Page 64 and 65: Leuner, C., Dressman, J., 2000. Imp
Page 66 and 67: Passerini, N., Albertini, B., Gonz
Page 68 and 69: Salonen, J., Lehto, V.-P., 2008. Fa
Page 70 and 71: Takeuchi, H., Nagira, S., Yamamoto,
Page 72 and 73: Vishweshwar, P., McMahon, J.A., Bis
show all

Mesoporous silica- and silicon-based materials ... - Helda - Helsinki.fi

Create successful ePaper yourself

Delete template?

Save as template?